BOMBAY-Since the Sept. 11 attacks on the US, the demand for the Bayer antibiotic Cipro has skyrocketed. As the only US-approved treatment for exposure to the deadly bacterium anthrax, the demand for the drug has been overwhelming.
Pharmaceutical companies in India, however, are ready to help ease the manufacturing burden. Working under Indian laws that prevent a company from using the same manufacturing process, but not the same ingredients when working with patented drugs, several large pharmaceutical companies have announced they are well stocked with the drug. These same companies have been making headlines during the past several years by providing generic AIDS cocktail drugs to African governments. While their work is not illegal in India, they are making generic versions of many drugs that currently hold patents in the US and abroad.
A two-month supply of 120 Cipro 500 mg pills in the US would cost $693 in comparison to the same generic prescription which Indian companies sell for $20.
Information from Reuters Health
I Was There: An Infection Preventionist on the COVID-19 Pandemic
April 30th 2025Deep feelings run strong about the COVID-19 pandemic, and some beautiful art has come out of those emotions. Infection Control Today is proud to share this poem by Carmen Duke, MPH, CIC, in response to a recent article by Heather Stoltzfus, MPH, RN, CIC.
From the Derby to the Decontam Room: Leadership Lessons for Sterile Processing
April 27th 2025Elizabeth (Betty) Casey, MSN, RN, CNOR, CRCST, CHL, is the SVP of Operations and Chief Nursing Officer at Surgical Solutions in Overland, Kansas. This SPD leader reframes preparation, unpredictability, and teamwork by comparing surgical services to the Kentucky Derby to reenergize sterile processing professionals and inspire systemic change.
Show, Tell, Teach: Elevating EVS Training Through Cognitive Science and Performance Coaching
April 25th 2025Training EVS workers for hygiene excellence demands more than manuals—it requires active engagement, motor skills coaching, and teach-back techniques to reduce HAIs and improve patient outcomes.